| | english | español | français |

  Home|RARM Forum|Online Forum|Past Activities|2008-2010|Transgenic pharmaplants   Printer-friendly version

Risk assessment and risk management of transgenic pharmaplants

This Discussion Group is now closed. All previous posts are available for reading by following the links in the "List of threads" at the bottom of this page

Introduction to the topic

by Dr. Robert K. D. Peterson, Montana State University, Bozeman, Montana, USA.

Pharmaceuticals using genetic engineering have been made through protein expression in bacterial, fungal, and mammalian cell cultures. Biotechnology is currently evolving to produce more complex and diverse pharmaceutical proteins in plants. Using plants offers the promise of large-scale production of therapeutic proteins. Continue reading »

Suggested points for discussion

  1. How to apply Annex III when assessing the risks of transgenic pharmaplants;
  2. Experience in conducting risk assessment of transgenic pharmaplants;
  3. Difficulties in accessing or reviewing baseline information related to the recipient and parental organisms, receiving environment, environmental interaction, etc.;
  4. Elements necessary to conduct risk assessments of transgenic pharmaplants;
  5. Issues that are unique to this topic;
  6. Recommendations for preparing risk assessment reports.

Selected readings

List of threads

Please choose among the links below to select a specific subject of discussion (so called "thread"). If you are signed-in, you may click on the "Create a new thread" button below the "List of threads" to begin a new topic of discussion. You may also click on the "Watch forum" button to receive all posts at your registered email address.